Status:

SUSPENDED

Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Lead Sponsor:

St. Jude Children's Research Hospital

Collaborating Sponsors:

National Heart, Lung, and Blood Institute (NHLBI)

Assisi Foundation

Conditions:

Severe Combined Immunodeficiency Disease, X-linked

Eligibility:

MALE

Up to 24 years

Phase:

PHASE1

PHASE2

Brief Summary

SCID-X1 is a genetic disorder of blood cells caused by DNA changes in a gene that is required for the normal development of the human immune system. The purpose of this study is to determine if a new ...

Detailed Description

Bone marrow CD34+ cells will be obtained in the operating room, transduced with the lentiviral vector that contains a normal copy of the γc gene, and reinfused without any myeloreductive conditioning....

Eligibility Criteria

Inclusion

  • \* Treatment Eligibility Criteria:
  • Age \<2 years at the time of enrollment.
  • No prior therapy with allogeneic stem cell transplantation.
  • A clinical diagnosis of SCID-X1 documented in the medical record.
  • A proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA.
  • Age \> 2 months to \< 1 year of age at the time of busulfan administration.
  • Less than 300 CD3+ T-cells by flow cytometry or higher if evidence of maternal engraftment as supported by peripheral blood FISH analysis for XY and XX.
  • Lymphocyte proliferation to phytohemagglutinin (PHA) \<10% of the lower limit of normal for the laboratory.
  • Treatment

Exclusion

  • Availability of a HLA matched sibling for allogeneic transplantation
  • Prior therapy with allogeneic stem cell transplantation
  • Positive for HIV infection by genome PCR
  • Presence of a medical condition indicating that survival will be less than 16 weeks such as the requirement for mechanical ventilation, severe failure of a major organ system, or evidence of a serious, progressive infection that is refractory to medical therapy.
  • The presence of any medical contraindications to general anesthesia and bone marrow harvest by aspiration
  • A social situation indicating that the family may not be able to comply with protocol procedures and recommended medical care.

Key Trial Info

Start Date :

August 17 2016

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2034

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT01512888

Start Date

August 17 2016

End Date

August 1 2034

Last Update

November 10 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University of California-San Francisco

San Francisco, California, United States, 94158

2

St. Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

3

Seattle Children's Research Institute

Seattle, Washington, United States, 98101